Baxalta Gmbh

Baxter International Inc.

Baxter Healthcare Sa

Takeda Pharmaceutical Company Limited

Michael Dockal

Friedrich Scheiflinger

Thomas Polakowski

Rudolf Hartmann

Hartmut Ehrlich

Ulrich Reineke

Frank Osterkamp

Eberhard Schneider

Peter Turecek

Meinhard Hasslacher

Ton That Hai

Paul Jeffrey Sanders

Markus Fries

Ulf Reimer

Ernst Böhm

Franziska Horling

Matthias Paschke

Sabine Knappe

Susanne Till

Bettina Hartlieb

Christian Fiedler

Hans Christian Hedrich

Cong Jiang

Klaus Tschetschkowitsch

Prasad Dande

Ernst Boehm

Andreas Goppelt

Andrea Sedivy

Zhenqing Zhang

Christina Szabo

Thomas Gatternig

Jadranka Koehn

Ernst BÖHM

Fritz Schleiflinger

Emst Bohm

Marianne Neurath

Ernst Bohm

Peter Leopold Turecek

Fritz Scheiflinger

The invention provides peptides that bind Tissue Factor Pathway Inhibitor (TFPI), including TFPI-inhibitory peptides, and compositions thereof. The peptides may be used to inhibit a TFPI, enhance thrombin formation in a clotting factor-deficient subject, increase blood clot formation in a subject, treat a blood coagulation disorder in a subject, purify TFPI, an identify a TFPI-binding compound.

TFPI inhibitors and methods of use

Disclosed herein are compositions and methods for improving hemostasis in the treatment of bleeding disorders and reversal of anticoagulant activity. Effective ratios of prothrombin (FII) and activated factor X (FXa) for the treatment of bleeding disorders that are as efficacious as FEIBA&#xae;, but require a lower concentration of FII are described herein.

Compositions of human prothrombin and activated factor X for improving hemostasis in the treatment of bleeding disorders

The invention provides peptides that bind Tissue Factor Pathway Inhibitor (TFPI), including TFPI-inhibitory peptides, and compositions thereof. The peptides may be used to inhibit a TFPI, enhance thrombin formation in a clotting factor-deficient subject, increase blood clot formation in a subject, and/or treat a blood coagulation disorder in a subject.

A peptide or peptide derivative comprising: A peptide or peptide derivative comprising:

Biologically active peptides

The invention provides peptides that bind Tissue Factor Pathway Inhibitor (TFPI), including TFPI-inhibitory peptides, and compositions thereof. Peptide complexes also are provided. The peptides may be used to inhibit a TFPI, enhance thrombin formation in a clotting factor-deficient subject, increase blood clot formation in a subject, treat a blood coagulation disorder in a subject, purify TFPI, and identify a TFPI-binding compound.

The invention provides peptides, including peptides that bind and, optionally, inhibit Protein S, and compositions thereof. The peptides may be used to, e.g., inhibit Protein S activity, enhance thrombin formation in a subject, increase blood clot formation in a subject, treat a blood coagulation disorder in a subject, purify Protein S, and identify a Protein S binding compound.

Peptides and methods of use

Methods and systems for activating Factor X are disclosed.

Factor X activation

Disclosed herein are methods for production of fully-processed mature Factor X in an expression system producing a controlled amount of furin between 50 U/mL and 300 U/mL of culture supernatant. Also disclosed are transformed cells, expression systems, and expression vectors for the expression of furin and Factor X.

Production of fully processed and functional factor X in a furin-secreting mammalian expression system

The invention provides a method of making a peptide or peptide derivative comprising the amino acid sequence comprising imfwydcye or a variant amino acid sequence comprising one, two, three, four, five or six amino acid substitutions in imfwydcye.

The present invention provides a preparation comprising fibrinogen and a sulfated polysaccharide as a one component composition or as a kit of parts comprising fibrinogen and sulfated polysaccharide as separated components. The present invention further provides a fibrin clot like structure obtainable by a defined process, a hemostatic patch, a two-component syringe system and various uses of the described preparations, fibrin clot like structures and patches.

Preparations based on fibrinogen and sulfated polysaccharides

The invention provides peptides that bind Tissue Factor Pathway Inhibitor (TFPI), including TFPI-inhibitory peptides, and compositions thereof. The peptides may be used to inhibit a TFPI, enhance thrombin formation in a clotting factor-deficient subject, increase blood clot formation in a subject, treat a blood coagulation disorder in a subject, purify TFPI, and identify a TFPI-binding compound.

Growing community of inventors

Vienna, Austria

Michael Dockal